Related Experiment Video
Updated: Jul 16, 2026

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
Published on: June 14, 2017
Fine characterization of mitral valve glycosaminoglycans and their modification with degenerative disease
Luca Dainese1, Gianluca Polvani, Fabio Barili
1Department of Cardiac and Vascular Surgery, Centro Cardiologico Monzino, IRCCS University of Milan, Milan, Italy.
Background:
The levels and fine structure of complex polysaccharides, glycosaminoglycans (GAGs), were determined in segments of the posterior mitral valve leaflet (MVL) taken from 15 patients affected by mitral regurgitation and degenerative disease and were compared with segments from 15 multiorgan donors.
Methods:
MVL GAGs were analyzed by agarose gel electrophoresis, and by HPLC and fluorophore-assisted carbohydrate electrophoresis to evaluate disaccharide patterns after treatment with chondroitinase ABC.
Results:
GAGs from the control group were composed of approximately 37% hyaluronic acid and 63% chondroitin sulfate/dermatan sulfate with a charge density of approximately 0.61. Chondroitin sulfate/dermatan sulfate polymers contained approximately 23% of the disaccharide sulfated in position 6 on N-acetyl-galactosamine, approximately 38% of the 4-sulfated disaccharide and approximately 2% of the non-sulfated disaccharide (with a 4-sulfated/6-sulfated ratio of 1.7). The total amount of GAGs was 0.66 microg/mg tissue. The total amount of GAGs in patients suffering from mitral regurgitation and degenerative disease was approximately 51.5% higher (although the difference was not significant, probably because of the low number of subjects enrolled in the study). However, significantly higher hyaluronic acid content (approx. +38%, p<0.05) and lower sulfated GAG content (approx. -21%, p<0.005) were demonstrated. As a consequence, the total charge density decreased by approximately 23% (p<0.005). This macro-modification of GAG composition was also followed by a micro-alteration of the structure of the sulfated polysaccharides, in particular with a significant decrease in the 4-sulfated disaccharide (and a parallel increase in hyaluronic acid content) with no modification of the percentage of the 6-sulfated and non-sulfated disaccharides (with a significant decrease in the 4-/6-sulfated ratio).
Conclusions:
We assume that changes in the relative amount and distribution of GAGs in posterior MVL in subjects suffering from mitral regurgitation and degenerative disease are consistent with a decrease in the tension to which these tissues are subjected and with an abnormal matrix microstructure capable of influencing the hydration and of conditioning the mechanical weakness of these pathological tissues.
Insights
Glycosaminoglycan (GAG) composition in mitral valve leaflets changes with mitral regurgitation, showing more hyaluronic acid and less sulfated GAGs. These alterations may weaken the tissue and affect its mechanical properties.
Area of Science:
- Biochemistry
- Cardiovascular Biology
- Tissue Engineering
Background:
- Investigated glycosaminoglycan (GAG) levels and structure in posterior mitral valve leaflets (MVL).
- Compared MVL tissue from patients with mitral regurgitation and degenerative disease to healthy controls.
Purpose of the Study:
- To determine the fine structure and levels of complex polysaccharides (GAGs) in MVL.
- To compare GAG composition between diseased and healthy mitral valve tissue.
Main Methods:
- Analyzed MVL GAGs using agarose gel electrophoresis.
- Employed HPLC and fluorophore-assisted carbohydrate electrophoresis for disaccharide pattern analysis after chondroitinase ABC treatment.
Main Results:
- Control MVL GAGs comprised 37% hyaluronic acid and 63% chondroitin sulfate/dermatan sulfate.
- Diseased MVL showed significantly higher hyaluronic acid (+38%) and lower sulfated GAGs (-21%), decreasing charge density by 23%.
- Alterations included a decrease in 4-sulfated disaccharides within sulfated polysaccharides.
Conclusions:
- Changes in GAG composition in mitral regurgitation suggest reduced tissue tension.
- Abnormal matrix microstructure may influence hydration and mechanical weakness in pathological MVL.
- Altered GAGs contribute to the mechanical dysfunction observed in mitral valve disease.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Stenosis I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Proteoglycans
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation I: Introduction

